Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other May 29 | 2024May CHMP Agenda; Noom and Ro GLP-1RA Ads Observed; NewAmsterdam Lp(a) ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other May 24 | 2024FDA Adcom Votes 4-7 Against Insulin Icodec T1DM ApprovalPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA May 24 | 2024Full FLOW Results at ERA; Lilly Increases Manufacturing Investment to $9BPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other May 23 | 2024Zealand Ph2a Dapiglutide Results; SixPeaks Launches as Obesity Startup with AZ Investment; Medtronic CY Q1 ’24 Earnings; Scholar Rock and Sagimet Investor Days; CLEAR Outcomes EU ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 22 | 2024New CGM Player to Enter the MarketPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other May 22 | 2024Novo to Face Uphill Battle; Insulin Icodec Adcom Briefing Documents AvailablePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 20 | 2024Fractyl Preclinical Rejuva Obesity Data; Hims and Hers to Sell Compounded Semaglutide; Sanofi T1DM Screening CampaignPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other May 17 | 2024Hengrui Licenses GLP-1RA-Based Assets to US Biotech; Inventiva Announces Positive DMC Recommendation for Ph3 MASH Trial; US Senate Releases Report on Anti-Obesity Medication Pricing; Biocon Q1 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA May 16 | 2024Lilly Ph3 QW Insulin Results; Roche Ph1 GLP-1/GIP RA Obesity Results; Zealand Q1 ’24 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Other May 15 | 2024Nanexa Receives CTA Approval for QM Liraglutide; Iconovo Files Patent for Inhaled GLP-1RAs; Sagimet, Galectin, and Dario Q1 ‘24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 14 | 2024Fractyl Q1 ’24 Earnings; 89bio Initiates Ph3 ENLIGHTEN-Cirrhosis; USPTO Extends Bempedoic Acid Patent; Inpefa HFpEF Post-Hoc AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery May 13 | 2024Senseonics and Terns Q1 2024 Earnings; New Abbott Libre CGMs Ad Observed; Neuraly Initiates Ph2 MASLD/MASH Trial; Cytokinetics Presents Ph3 SEQUOIA-HCM Results; Inventiva Publishes Ph2b MASH ResultsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other May 10 | 2024Lilly Partners for Cardiometabolic Drug Discovery; Insulet, 89bio, Arrowhead, and Akero Q1 ’24 Earnings; Medtronic Partners with Arecor for Implantable Pump; Senseonics Partners for Remote Care Platform; Noom Launches Movement Program for People on GLP-1RAsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other May 09 | 2024Novo Partners with Metaphore for Next-Gen Obesity Assets; Altimmune, Xeris, MannKind, and Viatris Q1 ’24 EarningsPurchase Blast
$599
Posted in: Other May 08 | 2024BI Partners with Walgreens for Clinical Trial Enrollment; Cytokinetics Initiates Pediatric Aficamten oHCM StudyPurchase Blast
$599
Posted in: Other May 07 | 2024Madrigal, Vertex, Ionis, Esperion, and Scholar Rock Q1 ‘24 Earnings; Tandem t:connect App RecalledPurchase Blast
$599
Posted in: Glucagon, Other May 06 | 2024Xeris Exclusively Partners with Beta Bionics; Eccogene IPO in 2025?Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, SGLT2i May 03 | 2024Novo London, Tandem, and Lexicon Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 02 | 2024Amgen, Regeneron, and Alnylam Q1 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other May 02 | 2024Novo to Face Two FDA Adcoms in 2024; Novo Q1 ‘24 EarningsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
